Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.21004DOI Listing

Publication Analysis

Top Keywords

successful desensitization
4
desensitization patient
4
patient lenalidomide
4
lenalidomide hypersensitivity
4
successful
1
patient
1
lenalidomide
1
hypersensitivity
1

Similar Publications

Desensitization is an immunological process that creates temporary tolerance to a drug, which disappears once treatment is discontinued. Ciprofloxacin is a commonly used antibiotic, particularly for chronic lung diseases, yet there are very few desensitization protocols for it. Two ciprofloxacin desensitization schemes were developed a long time ago.

View Article and Find Full Text PDF

Background: Antituberculosis drugs can cause hypersensitivity reactions that interrupt treatment and increase morbidity. Early identification and management are essential to prevent complications and drug resistance.

Objective: To evaluate the clinical characteristics, risk factors, and outcomes of antituberculosis drug-induced hypersensitivity reactions over a 10-year period in a tertiary referral center.

View Article and Find Full Text PDF

Introduction:  Taxanes, including paclitaxel, docetaxel, and cabazitaxel, are widely used anticancer agents that disrupt cell division by binding to microtubules, but are associated with significant adverse reactions, particularly infusion-related reactions (IRRs), such as flushing, urticaria, and respiratory symptoms. Despite premedication with steroids, antihistamines, and antiemetics per guidelines, taxane-induced side effects remain prevalent and can result in treatment delays or discontinuation, impacting patient outcomes. This study aimed to observe and document the incidence and spectrum of adverse reactions to taxanes among premedicated cancer patients to improve management and overall chemotherapy success.

View Article and Find Full Text PDF

Heart transplant candidates that are highly sensitized against human leukocyte antigens (HLA) face ongoing challenge in finding immunologically compatible donors. Desensitization strategies aimed at reducing HLA antibody titers have variable success rates. Imlifidase, a novel immunoglobulin G-degrading enzyme derived from Streptococcus pyogenes has been successfully used to eliminate pre-formed antibodies in sensitized kidney transplant recipients.

View Article and Find Full Text PDF